Melissa Muff‐Luett

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Gema Ariceta, Bradley P. Dixon, Seong Heon Kim et al. · Kidney International · 2020 · 90 citations · Full text

Medicine, Hematology, Pharmacology +15

Diagnosis, Treatment, and Outcomes in Children With Congenital Nephrogenic Diabetes Insipidus: A Pediatric Nephrology Research Consortium Study

Cynthia D’Alessandri-Silva, Melinda Carpenter, Rose Ayoob et al. · Frontiers in Pediatrics · 2020 · 37 citations · Full text

Medicine, Nephrology, Pediatrics +16

Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK)

Shina Menon, Kelli A. Krallman, Ayse Akcan‐Arikan et al. · Kidney International Reports · 2023 · 35 citations · Full text

Medicine, Nephrology, Pediatrics +12

Time to Continuous Renal Replacement Therapy Initiation and 90-Day Major Adverse Kidney Events in Children and Young Adults

Katja M. Gist, Shina Menon, Pilar Antón-Martín et al. · JAMA Network Open · 2024 · 29 citations · Full text

Medicine, Nephrology, Pediatrics +12

Continuous Kidney Replacement Therapy and Survival in Children and Young Adults: Findings From the Multinational WE-ROCK Collaborative

Michelle C. Starr, Katja M. Gist, Huaiyu Zang et al. · American Journal of Kidney Diseases · 2024 · 29 citations · Full text

Medicine, Nephrology, Pediatrics +14